scholarly journals Left ventricular thrombus in patients with COVID-19 – A case series

2021 ◽  
Vol 7 (1) ◽  
pp. 69
Author(s):  
Pankaj Jariwala ◽  
Arshad Punjani ◽  
Harikishan Boorugu ◽  
MariAjay Reddy
2021 ◽  
Vol 33 (4) ◽  
pp. 19-23
Author(s):  
Tarique S. Chachar ◽  
Nooraldaem Yousif ◽  
Khurshid Ahmed ◽  
Tajammul Hussain ◽  
Haitham Amin

Left ventricular thrombus (LVT) is a known complication of acute myocardial infarction (AMI). Vitamin K antagonists such as Warfarin showed a reduction in associated mortality and morbidity and are indicated as anticoagulants of choice in current guidelines. Since their approval for clinical use, there has been a dramatic increase in off-label use of direct oral anti-coagulants (DOAC) for LVT. In this case series, the authors share their successful experience with DOAC in the treatment of LVT.


2020 ◽  
Vol 4 (7) ◽  
pp. 1224-1229 ◽  
Author(s):  
Nithita Nanthatanti ◽  
Sithakom Phusanti ◽  
Pichika Chantrathammachart ◽  
Kanin Thammavaranucupt ◽  
Pantep Angchaisuksiri ◽  
...  

2017 ◽  
Vol 5 ◽  
pp. 2050313X1774521 ◽  
Author(s):  
Abeer Berry ◽  
Daniel Brancheau ◽  
Marcel Zughaib

It is a common medical practice to anticoagulate an asymptomatic left ventricular mural thrombus following an ST-elevation myocardial infarction using a vitamin K antagonist. Novel oral anticoagulants have not been studied extensively in this context, and therefore, no recommendations have been made for their use. A 67-year-old male physician with no significant medical history presented to the cardiology clinic complaining of shortness of breath that had been gradually worsening over a 2-week period and was found to have an anterior wall myocardial infarction with apical left ventricular thrombus that was treated with apixaban. We present a case of rapid resolution of left ventricular thrombus with the use of apixaban for anticoagulation. Although there are no guideline recommendations for this use, there have been case series and case reports that have shown safety and efficacy. Apixaban can be used for rapid resolution of left ventricular thrombus treatment.


2017 ◽  
Vol 44 (4) ◽  
pp. 519-524 ◽  
Author(s):  
Keaton S. Smetana ◽  
Jessie Dunne ◽  
Kevin Parrott ◽  
George A. Davis ◽  
Amy C. Schmelzer Collier ◽  
...  

2019 ◽  
Vol 8 ◽  
pp. 204800401983954 ◽  
Author(s):  
Reem A Bahmaid ◽  
Shoroq Ammar ◽  
Sarah Al-Subaie ◽  
Mohammed A Soofi ◽  
Hassan Mhish ◽  
...  

Background Left ventricular thrombus is a frequent complication of acute myocardial infarction and a risk factor for thromboembolic complications. Warfarin has been frequently used, but has some disadvantages that limit its use. Direct oral anticoagulants, in particular Dabigatran and Rivaroxaban have been proved to be effective in preventing thromboembolism among patients with non-valvular atrial fibrillation. However, no randomized clinical trials testing the efficacy and safety of these agents in patients with existing left ventricular thrombus. Furthermore, direct oral anticoagulants are still not approved by the Food and Drug Administration in the management of left ventricular thrombus. Method This study was a retrospective cohort assessing the efficacy of direct oral anticoagulants (Dabigatran or Rivaroxaban) on the resolution of left ventricular thrombus in patients taking either of these drugs during the study period from December, 2011 to December, 2016 at King Fahad Medical City. All patients’ records were reviewed and all patients who were diagnosed with left ventricular thrombus were included. Patients without available echocardiogram records were excluded. The study was approved by the institutional review board of King Fahad medical city, Riyadh Saudi Arabia. Result During the defined study period we found that 413 and 1218 patients were taking Dabigatran and Rivaroxaban, respectively. After filtering them based on the specialty of the prescriber, we ended up with 299 patients who have been started on Dabigatran and 448 patients who have been started on Rivaroxaban by cardiologists. Moreover, after reviewing echocardiogram reports for all of them (747 patients), we found that 11 patients were diagnosed to have left ventricular thrombus. Among those 11 patients, seven of them were treated with direct oral anticoagulants from the beginning and the remaining four patients were shifted from Warfarin to direct oral anticoagulants. All of them (7 patients) showed left ventricular thrombus resolution on follow-up echocardiogram. Conclusion Use of direct oral anticoagulants showed promising results in the resolution of left ventricular thrombus in patients diagnosed with left ventricular thrombus. Further studies at multiple health care centers are needed to further evaluate the efficacy and safety of direct oral anticoagulants as compared to traditional treatment in patients with left ventricular thrombus.


2020 ◽  
Vol 106 (S2) ◽  
Author(s):  
Alaa Solaiman Algazzar ◽  
Mohamed Ahmed Qutub ◽  
Abrar Abdulhamaid Maghrabi ◽  
Halimah Musa Alemshani ◽  
Hind Saeed Aloqbi

Sign in / Sign up

Export Citation Format

Share Document